Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparison of Rifaximin, Probiotics, and LOLA in Overt Hepatic Encephalopathy
NCT07037394Phase 4Completed
- Start
- Dec 2024
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of rifaximin, l-ornithine l-aspartate in hepatic encephalopathy (HE). Started Dec 2024; status: completed.
02
Drugs
rifaximinl-ornithine l-aspartate
03
Conditions
hepatic encephalopathy (HE)
Beyond the preview
Go deeper on NCT07037394.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07037394.